Valuation: Apogee Therapeutics, Inc.

Market Cap 9.99B 8.76B 8.09B 7.47B 14.16B 956B 14.45B 97.22B 37.77B 468B 37.5B 36.68B 1,624B P/E 2026 *
-30.9x
P/E 2027 * -23.9x
Enterprise Value 9.01B 7.9B 7.29B 6.74B 12.78B 862B 13.03B 87.68B 34.07B 422B 33.83B 33.08B 1,465B EV / Sales 2026 *
991x
EV / Sales 2027 * 740x
Free-Float
90.89%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Apogee Therapeutics, Inc.

1 day-0.22%
1 week+0.36%
Current month+0.39%
1 month+60.52%
3 months+60.31%
6 months+71.98%
Current year+76.54%
1 week 133.13
Extreme 133.13
133.87
1 month 81.59
Extreme 81.59
133.87
Current year 60.35
Extreme 60.35
133.87
1 year 34.34
Extreme 34.34
133.87
3 years 14.19
Extreme 14.19
133.87
5 years 14.19
Extreme 14.19
133.87
10 years 14.19
Extreme 14.19
133.87
Manager TitleAgeSince
Chief Executive Officer 36 31/08/2022
Director of Finance/CFO 60 31/12/2022
Chief Tech/Sci/R&D Officer - 30/04/2023
Director TitleAgeSince
Director/Board Member 54 21/06/2023
Director/Board Member 62 31/05/2023
Director/Board Member 36 31/05/2023
Date Insider Type Main position Quantity % Market Cap.
06-30Fiscal year

Chief Technology Officer

13,750 0.0246%
06-21Sell

Chief Executive Officer

-80,000 0.1429%
06-21Sell

Chief Technology Officer

-26,400 0.0471%
Change 5-day change 1-year change 3-year change Capi.($)
-0.22%+0.36%+265.97% - 9.99B
+0.59%+1.84%+2.20%+8.78% 49.42B
-0.36%+1.21%+420.77%+619.10% 40.34B
-2.13%+0.29%+23.91%-6.01% 34.01B
-2.29%+3.83%+23.48%+59.26% 33.56B
-0.79%+1.32%+5.78%+36.42% 26.84B
+3.82%+3.51% - - 17.22B
-2.62%-2.13%+64.96%+125.87% 15.19B
-2.17%+6.65%+104.31%+102.15% 13.96B
+1.01%-2.02%+13.47%+18.97% 13.36B
Average -0.51%+1.36%+102.76%+120.57% 25.39B
Weighted average by Cap. -0.57%+1.49%+101.91%+140.12%

Financials

2026 *2027 *
Net sales 9.09M 7.97M 7.36M 6.8M 12.89M 870M 13.15M 88.5M 34.39M 426M 34.14M 33.39M 1.48B 12.5M 10.96M 10.12M 9.35M 17.73M 1.2B 18.08M 122M 47.28M 586M 46.94M 45.91M 2.03B
Net income -318M -278M -257M -238M -450M -30.4B -459M -3.09B -1.2B -14.88B -1.19B -1.17B -51.65B -416M -365M -337M -312M -591M -39.88B -602M -4.05B -1.58B -19.51B -1.56B -1.53B -67.74B
Net Debt -980M -859M -793M -733M -1.39B -93.79B -1.42B -9.54B -3.7B -45.9B -3.68B -3.6B -159B -740M -649M -599M -554M -1.05B -70.88B -1.07B -7.21B -2.8B -34.68B -2.78B -2.72B -120B
Logo Apogee Therapeutics, Inc.
Apogee Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is advancing novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. APG777, the Company’s most advanced program, is being initially developed for the treatment of AD. With four validated targets in its portfolio, it is seeking to achieve efficacy and dosing through monotherapies and combinations of its novel antibodies. Its most advanced programs are APG777, APG990, APG333, and APG808. APG990 is an SQ extended half-life mAb that utilizes advanced antibody engineering to target OX40L. APG333 is a fully human mAb against thymic stromal lymphopoietin (TSLP). APG808 is an SQ extended half-life mAb targeting IL-4Ra. APG279 is for the dual inhibition of OX40L and IL-13.
Employees
261
Date Price Change Volume
08/07/26 US$133.25 -0.22% 2,543,882
07/07/26 US$133.54 +0.03% 1,054,061
06/07/26 US$133.50 +0.44% 1,595,460
02/07/26 US$132.91 +0.11% 2,998,799
01/07/26 US$132.77 +0.03% 3,598,433
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
15
Last Close Price
133.25USD
Average target price
130.53USD
Spread / Average Target
-2.04%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. APGE Stock